Pharmacogenetic association of the NPPA T2238C genetic variant with cardiovascular disease outcomes in patients with hypertension

JAMA

Volumn 299, Issue 3, 2008, Pages 296-307

  Lynch, Amy I ^a   Boerwinkle, Eric ^b   Davis, Barry R ^c   Ford, Charles E ^c   Eckfeldt, John H ^a   Leiendecker Foster, Catherine ^a   Arnett, Donna K ^d  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANTIHYPERTENSIVE AGENT; CHLORTALIDONE; DIURETIC AGENT; DOXAZOSIN; LISINOPRIL; ATRIAL NATRIURETIC FACTOR; NPPA PROTEIN, HUMAN; UNCLASSIFIED DRUG;

AGED; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIURETIC THERAPY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HEART INFARCTION; HOMOZYGOTE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; STROKE; SYSTOLIC BLOOD PRESSURE; UNITED STATES; GENETICS; MIDDLE AGED; PHARMACOGENETICS; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; AMLODIPINE; ANTIHYPERTENSIVE AGENTS; ATRIAL NATRIURETIC FACTOR; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CHLORTHALIDONE; DIURETICS; DOXAZOSIN; FEMALE; GENOTYPE; HUMANS; HYPERTENSION; LISINOPRIL; MALE; MIDDLE AGED; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 38349158422     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.299.3.296     Document Type: Article

References (25)

1. Thom T, Haase N, Rosamond W, et al. Heart disease and stroke statistics - 2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2006;113(6):e85-e151.
2. Centers for Disease Control and Prevention. Racial/ ethnic disparities in prevalence, treatment, and control of hypertension - United States, 1999-2002. MMWR Morb Mortal Wkly Rep. 2005;54(1):7-9.
3. Cadman PE, O'Connor DT. Pharmacogenomics of hypertension. Curr Opin Nephrol Hypertens. 2003;12(1):61-70.
4. Ackermann U. Structure and function of atrial natriuretic peptides. Clin Chem. 1986;32(2):241-247.
5. John SW, Krege JH, Oliver PM, et al. Genetic decreases in atrial natriuretic peptide and salt-sensitive hypertension. Science. 1995;267(5198):679-681.
6. Steinhelper ME, Cochrane KL, Field LJ. Hypotension in transgenic mice expressing atrial natriuretic factor fusion genes. Hypertension. 1990;16(3):301-307.
7. Deschepper CF, Boutin-Ganache I, Zahabi A, et al. In search of cardiovascular candidate genes: interactions between phenotypes and genotypes. Hypertension. 2002;39(2 pt 2):332-336.
8. Houweling AC, van Borren MM, Moorman AF, et al. Expression and regulation of the atrial natriuretic factor encoding gene NPPA during development and disease. Cardiovasc Res. 2005;67(4):583-593.
9. Kanfer A, Dussaule JC, Czekalski S, et al. Physiological significance of increased levels of endogenous atrial natriuretic factor in human acute renal failure. Clin Nephrol. 1989;32(2):51-56.
10. Liguori A, Di Gregorio F, Napoli C, et al. Atrial natriuretic factor and sympathetic activation in human heart failure. Riv Eur Sci Med Farmacol. 1994;16 (3-4):61-67.
11. Rubattu S, Stanzione R, Di Angelantonio E, et al. Atrial natriuretic peptide gene polymorphisms and risk of ischemic stroke in humans. Stroke. 2004;35(4):814-818.
12. Guo X, Cheng S, Taylor KD, et al. Hypertension genes are genetic markers for insulin sensitivity and resistance. Hypertension. 2005;45(4):799-803.
13. Dedoussis GV, Maumus S, Skoumas J, et al. Natriuretic peptide Val7Met substitution and risk of coronary artery disease in Greek patients with familial hypercholesterolemia. J Clin Lab Anal. 2006;20(3):98-104.
14. Rubattu S, Bigatti G, Evangelista A, et al. Association of atrial natriuretic peptide and type a natriuretic peptide receptor gene polymorphisms with left ventricular mass in human essential hypertension. J Am Coll Cardiol. 2006;48(3):499-505.
15. Rubattu S, Evangelista A, Barbato D, et al. Atrial natriuretic peptide (ANP) gene promoter variant and increased susceptibility to early development of hypertension in humans. J Hum Hypertens. 2007;21 (10):822-824.
16. Kato N, Sugiyama T, Morita H, et al. Genetic analysis of the atrial natriuretic peptide gene in essential hypertension. Clin Sci (Lond). 2000;98(3):251-258.
17. Davis BR, Cutler JA, Gordon DJ, et al; ALLHAT Research Group. Rationale and design for the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Am J Hypertens. 1996;9(4 pt 1):342-360.
18. Arnett DK, Boerwinkle E, Davis BR, et al. Pharmacogenetic approaches to hypertension therapy: design and rationale for the Genetics of Hypertension Associated Treatment (GenHAT) study. Pharmacogenomics J. 2002;2(5):309-317.
19. ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2000;283(15):1967-1975.
20. Cheng S, Grow MA, Pallaud C, et al. A multilocus genotyping assay for candidate markers of cardiovascular disease risk. Genome Res. 1999;9(10):936-949.
21. Hardy GH. Mendelian proportions in a mixed population. Yale J Biol Med. 2003;76(2):79-80.
22. Peterson B, George SL. Sample size requirements and length of study for testing interaction in a 2 x k factorial design when time-to-failure is the outcome [published correction appears in Control Clin Trials. 1994;15(4):326]. Control Clin Trials. 1993;14(6):511-522.
23. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288(23):2981-2997.
24. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group. Diuretic versus alpha-blocker as first-step antihypertensive therapy: final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension. 2003;42(3):239-246.
25. Kurland L, Lind L, Melhus H. Using genotyping to predict responses to anti-hypertensive treatment. Trends Pharmacol Sci. 2005;26(9):443-447.